Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BRENTUXIMAB: 180 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
180
Total FAERS Reports
47 (26.1%)
Deaths Reported
66
Hospitalizations
180
As Primary/Secondary Suspect
19
Life-Threatening
2
Disabilities

First Report: 20130401 · Latest Report: 20250818

What Are the Most Common BRENTUXIMAB Side Effects?

#1 Most Reported
Off label use
40 reports (22.2%)
#2 Most Reported
Drug ineffective
30 reports (16.7%)
#3 Most Reported
Disease progression
23 reports (12.8%)

All BRENTUXIMAB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Off label use 40 22.2% 13 21
Drug ineffective 30 16.7% 7 9
Disease progression 23 12.8% 6 2
Febrile neutropenia 14 7.8% 0 9
Malignant neoplasm progression 13 7.2% 7 7
Neuropathy peripheral 10 5.6% 0 5
Product use in unapproved indication 9 5.0% 2 5
Tubulointerstitial nephritis 9 5.0% 0 8
Acute kidney injury 8 4.4% 1 8
Pancytopenia 8 4.4% 1 6
Sepsis 8 4.4% 4 3
Vomiting 8 4.4% 1 5
C-reactive protein increased 7 3.9% 0 6
Covid-19 7 3.9% 4 6
Disease recurrence 7 3.9% 0 0
Drug ineffective for unapproved indication 7 3.9% 1 3
Guillain-barre syndrome 7 3.9% 0 7
Hodgkin's disease 7 3.9% 0 1
Myelosuppression 7 3.9% 0 7
Pyrexia 7 3.9% 1 2

Who Reports BRENTUXIMAB Side Effects? Age & Gender Data

Gender: 40.0% female, 60.0% male. Average age: 46.2 years. Most reports from: US. View detailed demographics →

Is BRENTUXIMAB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2013 1 0 0
2014 4 2 2
2015 3 1 2
2017 4 1 4
2018 6 1 4
2019 2 1 0
2020 2 1 2
2021 3 3 3
2022 8 3 4
2023 7 4 3
2024 4 0 2
2025 4 0 3

View full timeline →

What Is BRENTUXIMAB Used For?

IndicationReports
Hodgkin's disease 61
Diffuse large b-cell lymphoma 18
Cutaneous t-cell lymphoma 15
Product used for unknown indication 13
Chemotherapy 10
Anaplastic large cell lymphoma t- and null-cell types 9
Hodgkin's disease recurrent 8
Adult t-cell lymphoma/leukaemia 6
Non-hodgkin's lymphoma 5
Primary mediastinal large b-cell lymphoma recurrent 5

BRENTUXIMAB vs Alternatives: Which Is Safer?

BRENTUXIMAB vs BRENTUXIMAB VEDOTIN BRENTUXIMAB vs BREO ELLIPTA BRENTUXIMAB vs BREXANOLONE BRENTUXIMAB vs BREXPIPRAZOLE BRENTUXIMAB vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB vs BRIGATINIB BRENTUXIMAB vs BRILINTA BRENTUXIMAB vs BRILIQUE BRENTUXIMAB vs BRIMONIDINE BRENTUXIMAB vs BRIMONIDINE\BRINZOLAMIDE

Official FDA Label for BRENTUXIMAB

Official prescribing information from the FDA-approved drug label.